The pan-Canadian Pharmaceutical Alliance (pCPA): Negotiations Status Update

Home The pan-Canadian Pharmaceutical Alliance (pCPA): Negotiations Status Update

The pan-Canadian Pharmaceutical Alliance (pCPA) updated the status of negotiations on brand name drugs as of October 31, 2017:

  • 46 negotiations are currently underway with 2 new files added since the last update of September 30, 2017:
    • Gazyva (obinutuzumab): Used to treat follicular lymphoma
    • Lynparza (olaparib): Used to treat ovarian cancer
  • 177 joint negotiations have been completed with 7 new files added since the last update of September 30, 2017:
    • Erelzi (etanercept): Used to treat ankylosing spondylitis, polyarticular juvenile idiopathic arthritis, and rheumatoid arthritis
    • Humira (adalimumab): Used to treat hidradenitis suppurativa
    • Prolia (denosumab): Used to treat osteoporosis
    • Repatha (evolocumab): Used to treat primary hyperlipidemia and mixed dyslipidemia
    • Invokamet (canagliflozin/metformin hydrochloride): Used to treat type 2 diabetes mellitus
    • Kalydeco (ivacaftor): Used to treat cystic fibrosis with G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, S549R, G970R or R117H mutation
    • Kevzara (sarilumab): Used to treat rheumatoid arthritis
  • 55 drug products for which the pCPA has decided not to negotiate collectively or individually at the provincial-territorial level with no new files added since the last update of September 30, 2017.
  • 13 negotiations for brand name drug products have been recommended by the pCPA to be considered by each Province/Territory individually with no new files added since the last update of September 30, 2017.

For more information, please consult the pCPA’s website.

/ pCPA, What's New